[go: up one dir, main page]

MX2016014622A - Sistemas de suministro de medicamentos y metodos de uso relacionados. - Google Patents

Sistemas de suministro de medicamentos y metodos de uso relacionados.

Info

Publication number
MX2016014622A
MX2016014622A MX2016014622A MX2016014622A MX2016014622A MX 2016014622 A MX2016014622 A MX 2016014622A MX 2016014622 A MX2016014622 A MX 2016014622A MX 2016014622 A MX2016014622 A MX 2016014622A MX 2016014622 A MX2016014622 A MX 2016014622A
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery systems
related methods
active compound
biologically active
Prior art date
Application number
MX2016014622A
Other languages
English (en)
Inventor
Anderson David
Original Assignee
Textile-Based Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Textile-Based Delivery Inc filed Critical Textile-Based Delivery Inc
Publication of MX2016014622A publication Critical patent/MX2016014622A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente descripción se relaciona de manera general con sistemas de suministro de medicamento y métodos de uso relacionados. Los sistemas de suministro de medicamento pueden incluir una o más partículas, cada una de las cuales puede incluir un compuesto biológicamente activo dispersado en la misma. Los sistemas de suministro de medicamento también se pueden configurar para que presenten liberación de orden cero o de orden casi cero del compuesto biológicamente activo. Las partículas pueden ser de forma cilíndrica o similar a varilla, y pueden incluir una matriz interna polimérica que tiene un compuesto biológicamente activo dispersada en la misma, y una capa externa polimérica colocada por lo menos parcialmente alrededor de la matriz interna.
MX2016014622A 2014-05-30 2015-05-29 Sistemas de suministro de medicamentos y metodos de uso relacionados. MX2016014622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005772P 2014-05-30 2014-05-30
PCT/US2015/033410 WO2015184407A1 (en) 2014-05-30 2015-05-29 Drug delivery systems and related methods of use

Publications (1)

Publication Number Publication Date
MX2016014622A true MX2016014622A (es) 2017-05-04

Family

ID=54699938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014622A MX2016014622A (es) 2014-05-30 2015-05-29 Sistemas de suministro de medicamentos y metodos de uso relacionados.

Country Status (10)

Country Link
US (1) US20150342894A1 (es)
EP (1) EP3148494A4 (es)
JP (1) JP2017522365A (es)
KR (1) KR20170016884A (es)
CN (1) CN106456377A (es)
AU (1) AU2015266668A1 (es)
BR (1) BR112016025045A2 (es)
MX (1) MX2016014622A (es)
SG (1) SG11201608483PA (es)
WO (1) WO2015184407A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069898A1 (en) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
EP3400050B1 (en) * 2016-01-04 2020-12-23 Jurox Pty. Ltd. Drug release device and use
US11484591B2 (en) * 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
KR101957562B1 (ko) * 2017-03-30 2019-06-20 재단법인대구경북과학기술원 형상변형이 가능한 스캐폴드
WO2019222121A1 (en) * 2018-05-12 2019-11-21 Goldenbiotech, Llc Self-retaining implantable drug delivery device
MX2020012458A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US20230058726A1 (en) * 2018-08-22 2023-02-23 Ohio State Innovation Foundation Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
CN109821056A (zh) * 2019-02-21 2019-05-31 南方科技大学 栓塞剂及其制备方法和应用
CN110171814B (zh) * 2019-05-13 2022-07-29 电子科技大学 水溶性KCl催化合成碳纳米片的方法及储能、缓释应用
CN111956869B (zh) * 2020-08-07 2024-03-08 中南大学湘雅医院 一种缓慢促进神经生长的泵
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2023205140A1 (en) * 2022-04-18 2023-10-26 Colorado State University Research Foundation Thermoplastic elastomer composites, hydrogel composites, and gel polymer electrolyte composites

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
CA2363902C (en) * 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
CA2457979A1 (en) * 2001-08-31 2003-03-06 Schering Oy A delivery system
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2003094888A1 (en) * 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Processes for forming a drug delivery device
WO2004043435A2 (en) * 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
CN100512790C (zh) * 2005-06-03 2009-07-15 华中科技大学 零级控释给药系统及其制备方法
WO2010039717A1 (en) * 2008-09-30 2010-04-08 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of octreotide and methods of use thereof
EP2515864A4 (en) * 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
DK2547332T3 (en) * 2010-03-16 2018-12-17 Titan Pharmaceuticals Inc Heterogeneous implantable drug delivery devices

Also Published As

Publication number Publication date
SG11201608483PA (en) 2016-11-29
BR112016025045A2 (pt) 2017-08-15
JP2017522365A (ja) 2017-08-10
KR20170016884A (ko) 2017-02-14
CN106456377A (zh) 2017-02-22
US20150342894A1 (en) 2015-12-03
WO2015184407A1 (en) 2015-12-03
EP3148494A4 (en) 2017-12-20
AU2015266668A1 (en) 2016-11-03
EP3148494A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
IL260852B (en) Methods, devices and systems for pulmonary delivery of active agents
EP3250258A4 (en) Drug delivery methods and systems
MY187540A (en) Compounds active towards bromodomains
WO2017091749A8 (en) Shape changing drug delivery devices and methods
IL246706A0 (en) Fast-acting insulin preparations and pharmaceutical delivery systems
PL3160565T3 (pl) Urządzenia i systemy do dopłucnego dostarczania środków aktywnych
PL3160554T3 (pl) Urządzenia i systemy do dopłucnego dostarczania środków aktywnych
EP3122413A4 (en) Injectate delivery devices, systems and methods
EP3150202A4 (en) Drug carrier for tumour-specific targeted drug delivery and use thereof
WO2015017609A8 (en) Systems and methods for drug delivery, treatment, and monitoring
PH12016501841A1 (en) Immunosuppressant formulation
IL260287A (en) Controlled release agrochemical delivery units, their manufacture and use
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
IL273713A (en) Drug administration systems and related methods
EP3330379A4 (en) Aptamer against insulin receptor and pharmaceutical composition containing the same
ZA201906271B (en) Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament
IL274920A (en) Maytansinoid-based drug delivery systems
EP3137011A4 (en) Endodontic treatment with long term drug delivery system
WO2017066562A3 (en) Artificial metalloenzymes containing noble metal-porphyrins
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
IL253859B (en) Biologically active projectiles, systems, and methods
WO2016108507A3 (ko) 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제
PL3630188T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii